Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Surgery ; 156(1): 147-57, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24929764

ABSTRACT

BACKGROUND: Prospective uncontrolled study to investigate in papillary thyroid carcinoma (PTC) patients: (1) Distribution of lymph node metastases within the neck compartments, (2) factors predicting lymph nodes metastases, and (3) disease recurrence after thyroidectomy associated with radio-guided selective compartment neck dissection (RSCND). METHODS: We studied 345 consecutive PTC patients operated on between February 2004 and October 2011 at the S. Anna University Hospital, Ferrara (Italy). Patients with cervical lymph node metastases on preoperative ultrasonography and fine needle aspiration cytology were excluded. All patients underwent total thyroidectomy associated with SLN identification followed by RSCND in the SLN compartment, without SLN frozen section. RESULTS: In patients with lymph node metastases, metastatic nodes were not in the central neck compartment in 22.6% of the cases. The presence of infiltrating or multifocal PTC was a predicting factor for lymph nodes metastases. The median follow-up was 35.5 months. RSCND was associated with a false-negative rate of 1.1%, a persistent disease rate of 0.6%, and a recurrent disease rate of 0.9%. The permanent dysphonia rate was 1.3%. CONCLUSION: RSCND associated with total thyroidectomy may improve: (1) the locoregional lymph node staging, and (2) the identification of the site of lymphatic drainage within the neck compartments. Thus, considering the high false-negative rate of sentinel lymph node biopsy (SLNB), a radio-guided technique in PTC patients may guide the lymphadenectomy (ie, RSCND) to increase the metastatic yield and improve staging of the disease rather than avoid prophylactic lymphadenectomy (ie, SLNB).


Subject(s)
Carcinoma/surgery , Lymphoscintigraphy/methods , Neck Dissection/methods , Thyroid Neoplasms/surgery , Thyroidectomy , Adult , Aged , Carcinoma/diagnostic imaging , Carcinoma/pathology , Carcinoma, Papillary , False Negative Reactions , Female , Follow-Up Studies , Frozen Sections , Humans , Lymphatic Metastasis , Male , Middle Aged , Neck , Neoplasm Recurrence, Local , Neoplasm Staging , Prospective Studies , Sentinel Lymph Node Biopsy , Thyroid Cancer, Papillary , Thyroid Neoplasms/diagnostic imaging , Thyroid Neoplasms/pathology , Tomography, Emission-Computed, Single-Photon , Tomography, X-Ray Computed , Treatment Outcome
3.
Rheumatology (Oxford) ; 49(8): 1540-9, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20444860

ABSTRACT

OBJECTIVES: To perform an observational retrospective cross-sectional case-control study to evaluate prevalence, clinical patterns and outcomes of CNS involvement in a large cohort of primary SS (pSS) patients. METHODS: A total of 424 pSS patients, diagnosed according to the 2002 criteria proposed by the American-European Consensus Group, were checked for CNS involvement after exclusion of secondary causes. Demographic, clinical, seroimmunological data were compared between patients with and without CNS involvement. Neuroimaging data were also analysed. RESULTS: CNS involvement was detected in 25 (5.8%) patients (24 females and 1 male) both at disease onset (52%) and later (48%) with a mean latency after diagnosis of 7 years. Diffuse (40%), focal/multifocal (36%), multiple sclerosis (MS)-like disease (20%) and isolated optic neuritis (4%) were the most common CNS clinical pictures. Disease duration, lung involvement and decreased C(4) were associated with CNS involvement, while articular manifestations were more frequently observed in patients without neurological complications. Most cases had an acute, often recurrent course with spontaneous remission or only mild neurological impairment. CONCLUSIONS: CNS involvement represents a rare but not negligible complication of pSS, which may occur with a bimodal temporal pattern, both at onset and later, prompting attention in the differential diagnosis of apparently isolated neurological syndromes. Lung involvement emerged as the strongest risk factor for CNS involvement with a relative risk of 7.9, along with disease duration and decreased C(4).


Subject(s)
Central Nervous System Diseases/etiology , Sjogren's Syndrome/complications , Adult , Aged , Case-Control Studies , Central Nervous System Diseases/pathology , Central Nervous System Diseases/physiopathology , Cohort Studies , Disease Progression , Female , Humans , Italy/epidemiology , Magnetic Resonance Imaging , Male , Middle Aged , Regression Analysis , Retrospective Studies , Sjogren's Syndrome/pathology , Sjogren's Syndrome/physiopathology , Time Factors
4.
G Ital Cardiol (Rome) ; 11(11): 800-14, 2010 Nov.
Article in Italian | MEDLINE | ID: mdl-21348317

ABSTRACT

Cardiac resynchronization therapy (CRT) is a therapeutic option with proven efficacy in improving symptoms and reducing both hospitalization and mortality in patients with refractory heart failure. However, a significant number of patients do not respond to CRT and this may be due to incomplete or inappropriate selection and characterization of patients before pacemaker implant. Cardiac magnetic resonance imaging (CMRI) is an imaging technique that may assist cardiologists in this regard. This technique has the potential to improve the success rate of CRT, due to pre-interventional evaluation of left ventricular function, mechanical dyssynchrony, and characterization and quantification of scar tissue. Recently, venous coronary anatomy has also been successfully evaluated by CMRI. In this review the role of CMRI in patients with heart failure who are candidates for CRT is discussed and potential future developments are indicated.


Subject(s)
Cardiac Resynchronization Therapy/methods , Heart Failure/therapy , Magnetic Resonance Imaging/methods , Cicatrix/pathology , Coronary Vessels/anatomy & histology , Humans , Myocardial Contraction/physiology , Myocardial Infarction/pathology , Patient Selection , Ventricular Dysfunction, Left/physiopathology , Ventricular Function, Left/physiology
5.
J Nucl Med ; 49(8): 1299-304, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18632816

ABSTRACT

UNLABELLED: Our purpose was to evaluate the safety profile and biodistribution behavior in healthy human volunteers of the new myocardial perfusion tracer bis[(dimethoxypropylphosphanyl)ethyl]ethoxyethylamine N,N'-bis(ethoxyethyl)dithiocarbamato nitrido technetium(V) (99mTc-N-DBODC). METHODS: Ten healthy male volunteers were injected with 99mTc-N-DBODC under both stress and rest conditions. Anterior and posterior planar gamma-camera images were collected at 5, 30, 60, 240, and 1,440 min after injection, with organ uptake quantified by region-of-interest analysis. Tracer kinetics in body fluids were determined by collecting blood and urine samples at different time points. RESULTS: After injection, 99mTc-N-DBODC showed significant accumulation in the myocardium and prolonged retention. Under rest conditions, uptake in the heart, lungs, and liver at 5 min after injection was 1.67% +/- 0.13%, 1.16% +/- 0.07%, and 10.85% +/- 1.72%, respectively, of administered activity. Under stress conditions, heart uptake was significantly higher (2.07% +/- 0.22%). Radioactivity in the liver decreased to 3.64% +/- 0.98% and 2.37% +/- 0.48% at 60 and 240 min, respectively, after injection. This rapid liver clearance led to favorable heart-to-liver ratios, reaching values of 0.74 +/- 0.13 at rest and 1.26 +/- 0.28 during exercise 60 min after tracer administration. Radiation dose estimates were comparable to those obtained with other myocardial perfusion cationic compounds. CONCLUSION: The high uptake in the myocardium and the fast liver washout of 99mTc-N-DBODC will allow SPECT images of the left ventricle to be acquired early and with excellent quality.


Subject(s)
Heart/diagnostic imaging , Organophosphorus Compounds/pharmacokinetics , Organotechnetium Compounds/pharmacokinetics , Radiation Dosage , Radiopharmaceuticals/pharmacokinetics , Adult , Humans , Male , Middle Aged , Organ Specificity , Radionuclide Imaging , Whole Body Imaging
6.
Ann Surg Oncol ; 13(10): 1338-43, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16952022

ABSTRACT

BACKGROUND: We evaluated the incidence of sentinel lymph nodes (SLNs) in the internal mammary chain, calculated the lymphoscintigraphy and surgical detection rates, and evaluated the clinical effect on staging and the therapeutic approach in patients with breast cancer. METHODS: The study involved 741 women diagnosed with breast cancer eligible for the SLN technique. Lymphoscintigraphy was performed on the day before the operation by peritumoral injection of (99m)Tc-labeled nanocolloid. During the operation, a gamma probe was used to detect the SLN, which was then removed. RESULTS: A total of 719 SLNs were found in the axillary chain and 72 in the internal mammary chain. Preoperative lymphoscintigraphy showed 107 hot spots in the internal mammary chain, but only 72 SLNs in 65 patients were identified by the gamma probe and then removed with no complications. Of these 65 patients, 10 had a positive internal mammary chain SLN on final pathologic examination, whereas 55 patients had >or=1 negative SLNs on final pathologic analysis. Thirty-five (53%) of 65 patients had also an axillary SLN, but only 5 patients (8%) had a positive SLN on pathologic analysis. CONCLUSIONS: Evaluation of the SLNs in the internal mammary chain may provide more accurate staging in breast cancer patients. If an internal mammary sampling is not performed, patients may be understaged. This technique may allow better selection of those patients who will be submitted to adjuvant locoregional radiotherapy.


Subject(s)
Breast Neoplasms/pathology , Lymph Nodes/pathology , Sentinel Lymph Node Biopsy , Adult , Aged , Aged, 80 and over , Breast Neoplasms/diagnostic imaging , Breast Neoplasms/surgery , Female , Follow-Up Studies , Humans , Lymph Nodes/diagnostic imaging , Lymph Nodes/surgery , Lymphatic Metastasis , Middle Aged , Radionuclide Imaging
8.
Eur Heart J ; 26(18): 1838-45, 2005 Sep.
Article in English | MEDLINE | ID: mdl-15860518

ABSTRACT

AIMS: There is increasing evidence that stem cell (SC) mobilization to the heart and their differentiation into cardiac cells is a naturally occurring process. We sought to assess the safety and feasibility of granulocyte-colony stimulating factor (G-CSF) administration in humans to enhance SC mobilization and left ventricle (LV) injury repair during myocardial infarction (MI). METHODS AND RESULTS: Twenty patients with STEMI (mean age, 61+/-10 years), of whom 14 were submitted to primary percutaneous coronary intervention, were randomized to G-CSF (5 microg/kg/day s.c. for 4 consecutive days) or placebo. At entry and then at months 3 and 6, (99m)Tc-sestamibi gated-SPECT was performed to estimate extension of perfusion defect (PD) and LV function. The study drug was well tolerated and induced a significant increase of white blood count, CD34(+) cells, and CD34(+) cells coexpressing AC133 and VEGFR-2. At follow-up, treated and placebo groups did not differ for the angiographic coronary late loss and showed a similar pattern of PD recovery, whereas in the former at 6 months LVEF and especially LVEDV tended to be relatively higher (P=0.068) and lower (P=0.054), respectively. CONCLUSION: G-CSF administration in acute MI patients was feasible and did not lead to any clinical or angiographic adverse events and resulted in CD34(+) and CD34(+)AC133(+)VEGFR2(+) cell mobilization.


Subject(s)
Granulocyte Colony-Stimulating Factor/therapeutic use , Hematopoietic Stem Cell Mobilization/methods , Myocardial Infarction/therapy , Antigens, CD34 , Coronary Angiography , Coronary Circulation , Coronary Restenosis/etiology , Coronary Stenosis/therapy , Feasibility Studies , Female , Filgrastim , Humans , Male , Middle Aged , Myocardial Infarction/physiopathology , Recombinant Proteins , Recovery of Function , Single-Blind Method , Treatment Outcome , Ventricular Dysfunction, Left/therapy
9.
Best Pract Res Clin Rheumatol ; 18(6): 909-26, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15501189

ABSTRACT

The aim of this review is to summarise the clinical role of nuclear medicine in rheumatology taking into consideration the most specific diagnostic applications and other worthwhile therapeutic contributions. Traditional bone scintigraphy and recent inflammation-targeting radiopharmaceuticals, such as radiolabelled leucocytes and immunoscintigraphy, now allow us to obtain highly sensitive total-body and tomographical imaging information that can be used for the diagnosis of osteoarticular disease. The most common extra-articular manifestations of rheumatic diseases due to digestive, central nervous, respiratory and cardiovascular system involvement can be diagnosed by specific scintigraphic methods. Radiosynovectomy plays an important role in providing effective treatment for some joint diseases that are resistant to pharmacological therapy. Diagnostic and therapeutic applications of nuclear medicine show the highest efficacy in the early phase of rheumatic diseases. In more advanced stages, scintigraphical techniques play a complementary role to radiographical investigations in the assessment of prognosis and therapy efficacy.


Subject(s)
Radionuclide Imaging/methods , Radiopharmaceuticals/therapeutic use , Rheumatic Diseases/diagnostic imaging , Rheumatology/methods , Humans , Radioisotopes/therapeutic use , Rheumatic Diseases/complications , Rheumatic Diseases/radiotherapy , Synovial Membrane/pathology , Synovial Membrane/radiation effects , Synovitis/complications , Synovitis/radiotherapy
SELECTION OF CITATIONS
SEARCH DETAIL
...